Ganesh Housing Limited reported Q1 FY27 revenue of ₹280 crore, up 86% year-on-year, supported by the sale of the One91 Thaltej land parcel. EBITDA was weighed by higher land costs, while net profit was pressured by a one-time tax impact tied to an amalgamation. The company reiterated its FY27 guidance of ₹1,000–₹1,200 crore in revenue and ₹300–₹325 crore in net profit (PAT). The update strengthened market confidence in its project delivery and asset-monetization execution.

Wall Street has lowered its earnings expectations for Coinbase’s second quarter as the crypto market remained under pressure. Estimated quarterly trading volume is $152 billion, well below the market expectation of about $178 billion, and adjusted EBITDA is projected to come in roughly 3% under consensus due to weaker blockchain rewards and institutional trading revenue. The stock fell 1.7% to $165 during the session. The development reflects a shift in fundamentals for Coinbase as a single publicly listed stock and is not directly related to traditional, non-crypto assets.

Boston Scientific beat second-quarter estimates but lowered its 2026 sales and earnings outlook as restructuring costs weighed on guidance.

India’s Gland Pharma has received U.S. FDA approval for its abbreviated new drug application for Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL single-dose vials. The product is a bioequivalent generic version of Merck Sharp & Dohme’s Bridion Injection and is used to reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. The company said it launched the product on the day of approval through its marketing partner. U.S. sales for the product were around $1.6 billion in the 12 months ended April 2026, according to IQVIA data cited by Gland Pharma.

Jagsonpal Pharmaceuticals reported results for the June 2026 quarter (Q1FY27), with standalone net profit up 22.2% year on year to ₹132 million. Revenue rose 8.8% to ₹822 million, while EBITDA increased 21.4% to ₹191 million as the EBITDA margin expanded to 23.2% from 20.8%. The company attributed the performance to higher medical representative productivity and stronger sales in core brands, and said it outpaced the Indian pharma industry’s 11.6% average growth. The stock trades in India under the symbol ONUS.

Mangal Electrical Industries reported results for the quarter ended June 2026, with revenue of ₹125.83 crore, up 40.3% year on year. Net profit rose 101.5% to ₹7.52 crore, while earnings per share increased 49.5% to ₹2.72. The company attributed the profit increase to stronger revenue and a sharp drop in depreciation expenses following an accounting policy change. The quarterly performance is the company’s latest update and directly affects the value of its listed shares.

Metal Industrial Pte Limited and Sadhana Uday Chourasia sold 11.255 lakh shares of Maxgrow India Limited via an off-market transfer on July 28, 2026, cutting their combined holding to 89.78% from 92.82%. The sellers still control nearly 90% of voting rights, keeping effective control intact. The transaction is a shareholder reshuffle at an India-based unlisted real estate company and did not involve a public-market trade, a material change in control or any regulatory irregularity.

Grayscale executive Mintzberg filed a Form 144 on July 28, indicating plans to sell GXRP shares through Cantor Fitzgerald at $20.45 per share while retaining 2.84 million shares after the sale. The remaining stake is valued at roughly $58 million, or about 6% of U.S. spot XRP ETF total net assets of $971.6 million. The article notes it does not reference any traditional financial assets, with all instruments described as crypto-related trust products.